Abstract 2085P
Background
Pain symptoms are common among individuals with cancer, often necessitating pain management as part of cancer care. Opioids are thus mainstay in cancer care, notwithstanding the risk of adverse psychosocial sequelae associated with opioid use, including opioid use disorder (OUD). Buprenorphine is commonly used in managing OUD; however, it is unclear whether there are differences in the characteristics of individuals with cancer receiving buprenorphine, and what perioperative outcomes are associated with buprenorphine use.
Methods
We used data from Premier Health Database, a comprehensive electronic healthcare database with over 1,000 contributing healthcare systems and > 10 million inpatient admissions annually. We built a cohort of 616 patients undergoing surgical care for cancer between 2008 and 2020 who received buprenorphine as part of their care, and matched to 6,160 other patients with cancer randomly selected in the database who also underwent surgical care without receiving buprenorphine. We characterized demographic and clinical factors associated with receipt of buprenorphine, and also examined the association between receiving buprenorphine and perioperative outcomes, including length of stay (LOS, in days), hospitalization cost (in US dollars/$), and in-hospital mortality.
Results
Older individuals were less likely to receive buprenorphine (aOR = 0.95; 95% CI 0.94, 0.97), while patients with Medicaid insurance (aOR = 1.76; 95% CI 1.02, 3.03) and Medicare (aOR = 1.49; 95% CI 1.00, 2.24) were more likely to receive buprenorphine, compared to those with private insurance. We also found a significant association between radiation treatment and receipt of buprenorphine (aOR = 2.18; 95% CI 1.31, 3.61). In examining perioperative outcomes associated with receipt of buprenorphine, we found that while receipt of buprenorphine was not associated with in-hospital mortality, it was associated with decreased odds of being discharged home after care (aOR = 0.43; 95% CI 0.30, 0.63), increased hospital LOS (estimate = 3.50; 95% CI 2.79, 4.21), and increased overall cost of care (estimate = $10,353; 95% CI $7,846.54, $12,859.00).
Conclusions
Receipt of buprenorphine is also associated with odds of increased hospital LOS and increased cost of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06